A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Peterson, Kenneth R ^a   Costa, Flávia C ^a,d   Fedosyuk, Halyna ^a   Neades, Renee Y ^a   Chazelle, Allen M ^a   Zelenchuk, Lesya ^a,e   Fonteles, Andrea H ^a   Dalal, Parmita ^a   Roy, Anuradha ^b   Chaguturu, Rathnam ^b,f   Li, Biaoru ^c   Pace, Betty S ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; BUTYRIC ACID; FIREFLY LUCIFERASE; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HYDROXYUREA; VALERIC ACID; VALPROIC ACID; CD34 ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BETA GLOBIN GENE; BONE MARROW CELL; CELL ASSAY; CELL BASED HIGH THROUGHPUT SCREENING; CONTROLLED STUDY; CYTOTOXICITY; DIMERIZATION; DRUG IDENTIFICATION; ERYTHROID PRECURSOR CELL; GAMMA GLOBIN GENE; GENE; GENE EXPRESSION; GENE FUSION; GENE SWITCHING; HEMOGLOBIN SYNTHESIS; HEMOGLOBINOPATHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; TRANSGENIC MOUSE; WILD TYPE; YEAST ARTIFICIAL CHROMOSOME; ANIMAL; BIOSYNTHESIS; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE LOCUS; GENE TARGETING; GENE VECTOR; GENETICS; HEMOGLOBINOPATHIES; METABOLISM; PRECLINICAL STUDY; REPORTER GENE;

ANIMALS; ANTIGENS, CD34; BETA-GLOBINS; BONE MARROW CELLS; CHROMOSOMES, ARTIFICIAL, YEAST; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ERYTHROID PRECURSOR CELLS; FETAL HEMOGLOBIN; GAMMA-GLOBINS; GENE EXPRESSION REGULATION; GENE TARGETING; GENES, REPORTER; GENETIC LOCI; GENETIC VECTORS; HEMOGLOBINOPATHIES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MICE, TRANSGENIC;

EID: 84907270582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107006     Document Type: Article

References (42)

1. Ashley-Koch A, Yang Q, Olney RS (2000) Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol 151: 839-845.
2. Lancaster JR Jr (2003) Sickle cell disease: loss of the blood's WD40? Trends Pharmacol Sci 24: 389-391.
3. Vichinsky E (2002) New therapies in sickle cell disease. Lancet 360: 629-631.
4. Charache S (1997) Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol 34(3 Suppl 3): 15-21.
5. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, et al. (1997) Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 89: 1078-1088.
6. Davies SC, Gilmore A (2003) The role of hydroxyurea in the management of sickle cell disease. Blood Rev 17: 99-109.
7. DeSimone J, Heller P, Hall L, Zwiers D (1982) 5-azacytidine stimulates fetal hemoglobin synthesis (HbF) in anemic baboons. Proc Natl Acad Sci USA 79: 4428-4431.
8. Ley TJ, DeSimone J, Anagnou NP, Keller GH, Humphries RK, et al. (1982) 5- Azacytidine selectively increases γ-globin synthesis in a patient with β+ thalassemia. N Engl J Med 307: 1469-1475.
9. Letvin NL, Linch D, Beardsley GP, McIntyre KW, Nathan DG (1984) Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 310: 869-873.
10. Papayannopoulou T, Torrealba de Ron A, Veith R, Knitter G, Stamatoyannopoulos G (1984) Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. Science 224: 617-619.
11. Perrine SP, Rudolph A, Faller DV, Roman C, Cohen RA, et al. (1988) Butyrate infusions in the ovine fetus delays the biologic clock for globin gene switching. Proc Natl Acad Sci USA 85: 8540-8542.
12. Constantoulakis P, Papayannopoulou T, Stamatoyannopoulos (1988) α-amino- N-butyric acid stimulates fetal hemoglobin in the adult. Blood 72: 1961-1967.
13. Liakopoulou E, Blau CA, Li Q, Josephson B, Wolf JA, et al. (1995) Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 86: 3227-3235.
14. Little JA, Dempsey NJ, Tuchman M, Ginder GD (1995) Metabolic persistence of fetal hemoglobin. Blood 85: 1712-1718.
15. Hertzberg RP, Pope AJ (2000) High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 4: 445-451.
16. Fox S, Wang H, Sopchak L, Farr-Jones S (2002) High throughput screening 2002: moving toward increased success rates. J Biomol Screen 7: 313-316.
17. Cheng D, Yadav N, King RW, Swanson MS, Weinstein EJ, et al. (2004) Small molecule regulators of protein arginine methyltransferases. J Biol Chem 279: 23892-23899.
18. Ye QZ, Xie SX, Huang M, Huang WJ, Lu JP, et al. (2004) Metalloformselective inhibitors of E. coli methionine aminopeptidase and X-ray structure of a Mn(II)-form enzyme complexed with an inhibitor. J Am Chem Soc 126: 13940-13941.
19. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C et al. (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658.
20. Gaensler KM, Burmeister M, Brownstein BH, Taillon-Miller P, Myers RM (1991) Physical mapping of yeast artificial chromosomes containing sequences from the human β-globin gene region. Genomics 10: 976-984.
21. Rothstein RJ (1983) One-step gene disruption in yeast. Meth Enzymol 101: 202-210.
22. Peterson KR, Navas PA, Li Q, Stamatoyannopoulos G (1998) LCR-dependent gene expression in β-globin YAC transgenics: detailed structural studies validate functional analysis even in the presence of fragmented YACs. Hum Mol Genet 7: 2079-2088.
23. Peterson KR, Clegg CH, Huxley C, Josephson BM, Haugen HS, et al. (1993) Transgenic mice containing a 248-kb yeast artificial chromosome carrying the human β-globin locus display proper developmental control of human globin genes. Proc Natl Acad Sci USA 90: 7593-7597.
24. Blau CA, Peterson KR (2006) Establishment of cell lines that exhibit correct ontogenic stage-specific gene expression profiles from tissues of YAC transgenic mice using chemically induced growth signals. In: MacKenzie, A, editor. Methods in Molecular Biology, Vol. 349: YAC Protocols, 2nd ed. Totowa, NJ: Humana Press. pp. 163-173.
25. Hebiguchi M, Hirokawa M, Guo YM, Saito K, Wakui H, et al. (2008) Dynamics of human erythroblast enucleation. Int J Hematol 88: 498-507.
26. Blau CA, Barbas CF 3rd, Bomhoff A, Neades R, Yan J, et al. (2005) γ-globin gene expression in CID-dependent multi-potential cells established from β-YAC transgenic mice. J Biol Chem 280: 36642-36647.
27. Peterson KR, Zitnik G, Huxley C, Lowrey CH, Gnirke A, et al. (1993) Use of yeast artificial chromosomes (YACs) for studying control of gene expression: regulation of the genes of a human β-globin locus YAC following transfer to mouse erythroleukemia lines. Proc Natl Acad Sci USA 90: 11207-11211.
28. Vassilopoulos G, Navas PA, Skarpidi E, Peterson KR, Lowrey CH, et al. (1999) Correct function of the locus control region may require passage through a nonerythroid cellular environment. Blood 93: 703-712.
29. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73.
30. Auld DS, Thorne N, Nguyen DT, Inglese J (2008) A specific mechanism for nonspecific activation in reporter-gene assays. ACS Chem Biol 3: 463-470.
31. Roy A, Taylor BJ, McDonald PR, Price AR, Chaguturu R (2009) Hit-to-probeto- lead optimization strategies: a biological perspective to conquer the valley of death. In Seethala R, Zhang L, editors. Handbook of Drug Screening. Zug Switzerland: Informa Healthcare. pp. 21-55.
32. Boosalis MS, Castaneda SA, Trudel M, Mabaera R, White GL, et al. (2011) Novel therapeutic candidates, identified by molecular modeling, induce γ-globin expression in vivo. Blood Cells Mol Dis 47: 107-116.
33. Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, et al. (2010) Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA 107: 12617-12622.
34. Pais E, Cambridge JS, Johnson CS, Meiselman HJ, Fisher TC, et al. (2009) A novel high-throughput screening assay for sickle cell disease drug discovery. J Biomolec Screen 14: 330-336.
35. Haley JD, Smith DE, Schwedes J, Brennan R, Pearce C, et al. (2003) Identification and characterization of mechanistically distinct inducers of cglobin transcription. Biochem Pharmacol 66: 1755-1768.
36. Jin L, Siritanaratkul N, Emery DW, Richard RE, Kaushansky K, et al. (1998) Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci USA 95: 8093-8097.
37. Peterson KR, Li Q, Clegg CH, Furukawa T, Navas PA, et al. (1995) Use of YACs in studies of mammalian development: Production of β-globin locus YAC mice carrying human globin developmental mutants. Proc Natl Acad Sci USA 92: 5655-5659.
38. Graslund T, Li X, Magnenat L, Popkov M, Barbas CF 3rd (2005) Exploring strategies for the design of artificial transcription factors. J Biol Chem 280: 3707-3714.
39. Tschulena U, Peterson KR, Gonzalez B, Fedosyuk H, Barbas CF 3rd (2009) Positive selection of DNA-protein interactions in mammalian cells through phenotypic coupling with retrovirus production. Nat Struct Mol Biol 16: 1195-1199.
40. Muralidhar SA, Ramakrishnan V, Kalra IS, Li W, Pace BS (2011) Histone deacetylase 9 activates γ-globin gene expression in primary erythroid cells. J Biol Chem 286: 2343-2353.
41. Kalra IS, Alam MM, Choudhary PK, Pace BS (2011) Krüppel-like factor 4 activates HBG gene expression in primary erythroid cells. Br J Haematol 154: 248-259.
42. Kuhn RM, Ludwig RA (1994) Complete sequence of the yeast artificial chromosome cloning vector pYAC4. Gene 141: 125-127.